News Release(2020)

December 10, 2020

The Efficacy and Safety Results of the Overseas Phase-III Long-Term Study of Uterine Fibroids for GnRH Antagonist, Linzagolix, conducted by ObsEva

November 24, 2020

Submission of Marketing Authorization Application to the European Medicines Agency for Linzagolix for the treatment of uterine fibroids

October 9, 2020

Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease

July 6, 2020

Positive Results from Uterine Fibroids Phase-III Clinical Trials (PRIMROSE 1 and PRIMROSE 2) of Linzagolix

March 27, 2020

Licensing Agreement for CG0070, a Drug for Bladder Cancer

February 25, 2020

Transfer of Distribution Operation of MINIRIN MELT® and DESMOPRESSIN Formulations

February 3, 2020

Transfer of Distribution Operation of MARIZEV® Type-2 Diabetes Treatment

January 22, 2020

Kissei Announces the Publication of the Results of Phase III Clinical Trials of Rovatirelin for the Treatment of Spinocerebellar Degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry